Syneron Medical Ltd. (NSDQ:ELOS) agreed to pony up $31 million plus royalties for the rights to a pair of Palomar Medical Technologies (NSDQ:PMTI) patents for laser- and light-based hair removal technologies, ending a long-running legal battle.
SyntheMed and Pathfinder become Pathfinder Cell Therapy after merger | Acquisitions Roundup
Closing an agreement that’s been in the works since January, SyntheMed, Inc. (OTC:SYMD), a biomaterials company, changed its name to Pathfinder Cell Therapy, after merging with the biotechnology company.
Richard Franklin, who was President & CEO of Pathfinder, will keep his corner office and Joerg Gruber, a former director of SyntheMed will serve as chairman of the board for the newly created company.
Whistleblower to SNN: Cough up sales docs | MassDevice.com Legal Roundup
A former Smith & Nephew (NYSE:SNN) executive wants a Tennessee federal court to force the company to cough up documents detailing its sales to the U.S. government as part of his whistleblower lawsuit accusing the firm of breaking the Trade Agreements Act.
Arthrocare gets FDA nod for shoulder suture system | Regulatory Roundup
ArthroCare Corp. (NSDQ:ATRC) landed FDA clearance for its SpeedFix suture system for repairing tears in the shoulder joint, a common injury.
The sutures tout independent bone locking, suture tensioning and suture locking to fasten tissue to bone using double-loaded proprietary MagnumWire sutures.
The company won FDA clearance for their SpeedFix anchor system in November 2010.
Indian market opens to InspireMD mesh coronary stent | Deals roundup
InspireMD Inc. (OTC:NSPR) launched its MGuard coronary stent system in India.
The Tel Aviv-based firm’s flagship product is the first mesh-based coronary stent system available in the country, the company said.
The CE Mark approved MGuard stent is wrapped with a polymer mesh sleeve designed to protect acute MI patients against embolism. Kirloskar Technologies P. Ltd., which has already closed an initial order for the stent in India, will be InspireMD’s distributor of the product, according to the company.
Caliper and HistoRx collaborate on biomarkers | Distribution roundup
Here’s a roundup of companies announcing new distribution deals.
FDA clears Teleflex’s VasaNova catheter locator | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
Insulet inks Canadian deal with GlaxoSmithKline | Distribution roundup
Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.
Medtronic trumpets 12-year heart valve study | Research roundup
After 12 years, Medtronic Inc.’s (NYSE:MDT) Mosaic bioprosthetic heart valves are still working, according to a study published online in The Journal of Thoracic and Cardiovascular Surgery.
The Minneapolis-based medical device giant touted the study that evaluated the performance of its Mosaic valve in patients who had aortic valve replacement (AVR) and mitral valve replacement (MVR).
Caliper captures CRi for $20 million
Caliper Life Sciences Inc. (NSDQ:CALP) agreed to buy Woburn, Mass.-based Cambridge Research & Instrumentation Inc.
The $20 million deal will see Caliper acquire all of CRi’s outstanding equity securities in exchange for common stock valued at about $10.5 million and $7.5 million in cash plus the assumption of $2 million in debt.
Caliper Life Sciences back in the black after Q1 loss
For the second time in the past three quarters, Caliper Life Sciences Inc. (NSDQ:CALP) made a profit.
At many companies, that would hardly qualify as news. But at Caliper — at least since early 2001 — net income of any size was missing in action. The Hopkinton, Mass.-based laboratory instruments and service provider racked up 34 consecutive quarters of net losses, generating a $294-million gusher of red ink before snapping that streak during the final three months of 2009.
